Please assess the completion status of the following clinical trial:

Trial Title: Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic insomnia defined as a) sleep onset latency and/or wake after sleep onset longer than 30 minutes per night, at least 3 nights per week; and b) Insomnia duration of at least 6 months, by self-report; and c) minimum of 1 daytime complaint by self-report (e.g. fatigue, mood disturbance);~* Between 18 and 65 years of age;~* English-speaking;~* Literate;~* Mentally intact;~* Interested in either medication or mind-body interventions;~* Able to attend weekly classes in a Minnesota Metro area;~* Able to comply with study sleep monitoring requirements;~* Willing to complete the informed consent process.~Exclusion Criteria:~* Sleep apnea or other primary sleep disorder suspected of being responsible for insomnia;~* Mental disorder or substance (including medications) suspected of being responsible for insomnia;~* General medical condition suspected of being responsible for the insomnia;~* Medically unstable (a hospital admission for non-elective purposes in the last 3 months or major surgery planned in the next 3 months);~* Serious preexisting mental health issues: suicidality or thought disorder/psychosis; or delirium or substance abuse;~* Treatment for depression or anxiety with initiation of therapy or dosage change within the last 6 months;~* Use of non-prescription sleep aids and unwilling or unable to discontinue these during the study;~* Use of prescription sleep medications or other medications known to affect sleep or be contraindicated with use of hypnotics, and unwilling or unable to discontinue these during the study;~* Known allergy to eszopiclone;~* Shift worker;~* Pregnant , breast-feeding or planning pregnancy in next 6 months;~* Previous cognitive behavioral therapy for insomnia or current psychotherapy;~* Prior MBSR class or regularly practicing mindfulness meditation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MBSR (Type: EXPERIMENTAL): A Mindfulness-Based Stress Reduction (MBSR) program that includes 8-weeks of group instruction in mindfulness meditation techniques followed by home practice and monitoring.
- PCT Sleeping Pills (Type: ACTIVE_COMPARATOR): A pharmacotherapy control arm (PCT Sleeping Pills) consisting of a state-of-the-art prescription sedative hypnotic, eszopiclone - brand name LUNESTA(R), at a dose of one 3 milligram (mg) pill nightly for a duration of 8 weeks followed by use as needed (same dosage) for 3 months. This drug was approved by the Food and Drug Administration as a sedative for more than short term use.

Based on this trial design, predict the completion outcome and termination type (if applicable).